Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Silence Therapeutics plc logo — Precision Engineered Medicines to Silence Diseases

Silence Therapeutics plc

Precision Engineered Medicines to Silence Diseases

Founded 1999 United Kingdom London, United Kingdom 109 employees Post-IPO Equity Total: $248.70M Biotechnology, Health Care +2

General Information

Company Name Silence Therapeutics plc
Founded Year 1999
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 109
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Silence Therapeutics plc. To contact Silence Therapeutics plc, visit silence-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Silence Therapeutics plc compare?

A PDF of Silence Therapeutics plc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Silence Therapeutics plc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Silence Therapeutics plc

Silence Therapeutics is a biotechnology company founded in 1999 in the United Kingdom, specializing in RNA interference (RNAi) technology. The company's validated mRNAi GOLD™ platform has positioned it as a sought-after partner for pharmaceutical companies seeking to harness the benefits of siRNA in their drug discovery pipelines. With a focus on developing a new generation of medicines, Silence Therapeutics aims to address the unmet needs of patients with limited treatment options. The company's commitment to leveraging technology for therapeutic advancements is underscored by its development of a deep pipeline of innovative siRNAs based on the mRNAi GOLD™ platform. This approach targets diseases with a genetic basis, offering versatility and potential for addressing a wide range of conditions across various therapeutic areas. Notably, the company received a significant $120.00M post-IPO equity investment on February 2, 2024, with contributions from prominent investors including 5AM Ventures, Vivo Capital, Redmile Group, Logos Capital, Nextech Invest, TCG Crossover, and Frazier Life Sciences. This investment reflects confidence in Silence Therapeutics' potential to drive positive outcomes for patients while delivering value to shareholders.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $120.00M 7
5AM Ventures Vivo Capital Redmile Group
5AM Ventures, Vivo Capital +5
02 Feb 2024
Post IPO Equity $20.00M 1
Frazier Healthcare Partners
Frazier Healthcare Partners
05 Nov 2021
Post IPO Equity $45.50M 2
Adage Capital Management
Adage Capital Management, Biotechnology Value Fund
18 Feb 2021
Post IPO Equity $5.00M -
18 Jul 2019
Post IPO Equity $58.20M -
08 Apr 2015

Silence Therapeutics plc Alternatives & Competitors

View All Alternatives
Silence Therapeutics plc vs
Judo Bio
Judo Bio United States

Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic...

Series A
32 employees
Biotechnology, Health and Wellness
Compare Silence Therapeutics plc vs Judo Bio
Silence Therapeutics plc vs
Gemini Therapeutics
Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therap...

Post-IPO Equity
Biopharma, Biotechnology
Compare Silence Therapeutics plc vs Gemini Therapeutics
Silence Therapeutics plc vs
Code Biotherapeutics
Code Biotherapeutics United States

Pioneering targeted delivery of precision genetic medicines

Series A
23 employees
Biotechnology, Health Care
View all alternatives

FAQ About Silence Therapeutics plc

Precision Engineered Medicines to Silence Diseases
Silence Therapeutics plc was founded in 1999.
Silence Therapeutics plc is headquartered in London, United Kingdom.
Silence Therapeutics plc operates in Biotechnology, Health Care, Health and Wellness and Information Technology.
Silence Therapeutics plc has approximately 109 employees.
Silence Therapeutics plc has completed 5 funding rounds, raising a total of $248.70M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Silence Therapeutics plc include Judo Bio, Gemini Therapeutics, Code Biotherapeutics, Arcturus Therapeutics, Hopewell Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Silence Therapeutics plc and Judo Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Silence Therapeutics plc, https://bouncewatch.com/company/silence-therapeutics, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout